TaiMed Biologics Announces Positive Results in Clinical Trial for New HIV Drug

TaiMed Biologics announced yesterday (January 7) that its long-acting monoclonal antibody drugs, TMB-365 and TMB-380, have shown significant positive results in a Phase 2a clinical trial for HIV treatment, with a two-month dosing regimen. The trial successfully met all primary clinical endpoints, with no treatment failures reported among the participants who completed the trial.